Agency Forms Undergoing Paperwork Reduction Act Review, 57757-57758 [2017-26399]

Download as PDF 57757 Federal Register / Vol. 82, No. 234 / Thursday, December 7, 2017 / Notices DEPARTMENT OF HEALTH AND HUMAN SERVICES Centers for Disease Control and Prevention [30Day–17–17ACE] Agency Forms Undergoing Paperwork Reduction Act Review sradovich on DSK3GMQ082PROD with NOTICES In accordance with the Paperwork Reduction Act of 1995, the Centers for Disease Control and Prevention (CDC) has submitted the information collection request titled MedicationAssisted Treatment (MAT) for Opioid Use Disorders Study to the Office of Management and Budget (OMB) for review and approval. CDC previously published a ‘‘Proposed Data Collection Submitted for Public Comment and Recommendations’’ notice on June, 19, 2017 to obtain comments from the public and affected agencies. CDC received three comments related to the previous notice. This notice serves to allow an additional 30 days for public and affected agency comments. CDC will accept all comments for this proposed information collection project. The Office of Management and Budget is particularly interested in comments that: (a) Evaluate whether the proposed collection of information is necessary for the proper performance of the functions of the agency, including whether the information will have practical utility; (b) Evaluate the accuracy of the agencies estimate of the burden of the proposed collection of information, including the validity of the methodology and assumptions used; (c) Enhance the quality, utility, and clarity of the information to be collected; (d) Minimize the burden of the collection of information on those who are to respond, including, through the use of appropriate automated, electronic, mechanical, or other technological collection techniques or other forms of information technology, e.g., permitting electronic submission of responses; and (e) Assess information collection costs. To request additional information on the proposed project or to obtain a copy of the information collection plan and instruments, call (404) 639–7570 or send an email to omb@cdc.gov. Direct written comments and/or suggestions regarding the items contained in this notice to the Attention: CDC Desk Officer, Office of Management and Budget, 725 17th Street NW., Washington, DC 20503 or by fax to (202) 395–5806. Provide written comments within 30 days of notice publication. Proposed Project Evaluation of Medication-Assisted Treatment (MAT) for Opioid Use Disorder—New—National Center for Injury Prevention and Control (NCIPC), Centers for Disease Control and Prevention (CDC). Background and Brief Description This is a new Information Collection Request. CDC requests a three-year OMB approval. About 2 million people aged 12 or older in the United States have Opioid Use Disorders (OUDs) related to prescription opioids and almost 600,000 have OUDs related to heroin use (SAMHSA, 2015). OUD is a problematic pattern of opioid use that cause significant impairment or distress characterized by unsuccessful efforts to control use and failures to fulfill obligations social, at work, or school, yet many of these people do not receive OUD treatment. Given the continued need for treatment and the urgency of the opioid epidemic, further understanding of the individual and contextual factors that may impact treatment outcomes is needed. To help address this need, the CDC is conducting a study of 60 Opioid Use Disorder (OUD) treatment facilities and four primary care facilities located in 11 metropolitan statistical areas across the United States. The respondent universe includes individuals in the United States who receive some form of OUD treatment in the 11 MSAs. Prospective participants will be eligible if they are 18 to 64 years of age and initiating one of four primary treatments for OUD: Methadone maintenance treatment (MMT), buprenorphine (BUP), naltrexone (NTX), or counseling treatment without medication (COUN). The study aims to enroll 3,560 clients across all sites to better understand the relationship between type of Medication Assisted Treatment (MAT) and individual and treatment facility characteristics, and contextual factors. The information gained from this data collection will help inform policy makers, communities, and providers on how individual characteristics and contextual factors may impact client outcomes. The MAT study will also provide a unique perspective for three reasons: (1) It assesses the treatment, individual, and contextual factors that influence implementation and outcomes in real-world settings; (2) its large target sample size (n = 3,560); and, (3) the long follow-up window (i.e., 24-month follow-up period with clients). CDC has collaborated with other relevant federal agencies to avoid duplication and maximize efficiencies in data collection. The MAT Study design and protocols have been reviewed and shared with colleagues from the Substance Abuse and Mental Health Services Administration (SAMHSA) and the National Institute on Drug Abuse (NIDA). Four overarching evaluation questions guide the MAT Study. These questions drive the research design, and CDC developed this data collection effort to, specifically, address these evaluation questions. This data collection effort captures a series of outcome measures including the associated benefits (e.g., reductions in morbidity, mortality, and drug overdoses; improvements in socioeconomic outcomes and healthrelated quality of life [HRQOL]) and potential risks (e.g., side effects, diversion potential) of each treatment alternative. The study will use a mixed-methods approach using quantitative methods such as multilevel latent growth models, propensity score matching, latent class analysis and advanced mediation analysis and qualitative methods such as interactive coding and analysis for common themes. The total estimated annualized burden for this collection is 3,093 hours. The only cost to respondents will be time spent responding to the surveys. ESTIMATED ANNUALIZED BURDEN HOURS Number of respondents Type of respondents Form name Clients ............................................................. Client Screener .............................................. Client Check-In ............................................... VerDate Sep<11>2014 18:50 Dec 06, 2017 Jkt 244001 PO 00000 Frm 00055 Fmt 4703 Sfmt 4703 E:\FR\FM\07DEN1.SGM 1,583 1,187 07DEN1 Number of responses per respondent 1 2 Average burden per response (in hours) 5/60 15/60 57758 Federal Register / Vol. 82, No. 234 / Thursday, December 7, 2017 / Notices ESTIMATED ANNUALIZED BURDEN HOURS—Continued Number of respondents Type of respondents Form name Treatment facility staff ..................................... Client Questionnaire Baseline ........................ Client Questionnaire 12-Month Follow-up ..... Client Questionnaire 24-Month Follow-up ..... Client Focus Groups ...................................... Staff Focus Groups ........................................ Leroy A. Richardson, Chief, Information Collection Review Office, Office of Scientific Integrity, Office of the Associate Director for Science, Office of the Director, Centers for Disease Control and Prevention. [FR Doc. 2017–26399 Filed 12–6–17; 8:45 am] BILLING CODE 4163–18–P DEPARTMENT OF HEALTH AND HUMAN SERVICES Centers for Disease Control and Prevention [Docket Number CDC–2017–0104, NIOSH– 304] Draft—National Occupational Research Agenda for Traumatic Injury Prevention National Institute for Occupational Safety and Health (NIOSH) of the Centers for Disease Control and Prevention (CDC), Department of Health and Human Services (HHS). ACTION: Request for comment. AGENCY: The National Institute for Occupational Safety and Health of the Centers for Disease Control and Prevention announces the availability of a draft NORA Agenda entitled National Occupational Research Agenda for Traumatic Injury Prevention for public comment. To view the notice and related materials, visit https:// www.regulations.gov. and enter CDC– 2017–0104 in the search field and click ‘‘Search.’’ SUMMARY: sradovich on DSK3GMQ082PROD with NOTICES Table of Contents • • • • • Dates Addresses For Further Information Contact Supplementary Information Background Electronic or written comments must be received by February 5, 2018. ADDRESSES: You may submit comments, identified by CDC–2017–0104 and docket number NIOSH–304, by any of the following methods: DATES: VerDate Sep<11>2014 18:50 Dec 06, 2017 Jkt 244001 • Federal eRulemaking Portal: https://www.regulations.gov. Follow the instructions for submitting comments. • Mail: National Institute for Occupational Safety and Health, NIOSH Docket Office, 1090 Tusculum Avenue, MS C–34, Cincinnati, Ohio 45226–1998. Instructions: All submissions received in response to this notice must include the agency name and docket number [CDC–2017–0104; NIOSH–304]. All relevant comments received will be posted without change to https:// www.regulations.gov, including any personal information provided. For access to the docket to read background documents or comments received, go to https://www.regulations.gov. All information received in response to this notice will also be available for public examination and copying at the NIOSH Docket Office, 1150 Tusculum Avenue, Room 155, Cincinnati, OH 45226–1998. FOR FURTHER INFORMATION CONTACT: Emily Novicki (NORACoordinator@ cdc.gov), National Institute for Occupational Safety and Health, Centers for Disease Control and Prevention, Mailstop E–20, 1600 Clifton Road NE., Atlanta, GA 30329, phone (404) 498– 2581 (not a toll free number). SUPPLEMENTARY INFORMATION: The National Occupational Research Agenda (NORA) is a partnership program created to stimulate innovative research and improved workplace practices. The national agenda is developed and implemented through the NORA sector and cross-sector councils. Each council develops and maintains an agenda for its sector or cross-sector. Background: The National Occupational Research Agenda for Traumatic Injury Prevention (the Agenda) is intended to identify the research, information, and actions most urgently needed to prevent occupational traumatic injuries. The National Occupational Research Agenda for Traumatic Injury Prevention provides a vehicle for industry stakeholders to describe the most relevant issues, gaps, and safety and health needs for the cross-sector. Each NORA research agenda is meant to guide or promote PO 00000 Frm 00056 Fmt 4703 Sfmt 4703 Number of responses per respondent 1,187 930 744 27 27 Average burden per response (in hours) 1 1 1 1 1 52/60 45/60 45/60 90/60 90/60 high priority research efforts on a national level, conducted by various entities, including government, higher education, and the private sector. This is the first Traumatic Injury Prevention Agenda, developed for the third decade of NORA (2016–2026). The Agenda was developed considering information about injuries, the state of the science, and the probability that new information and approaches will make a difference. As the steward of the NORA process, NIOSH invites comments on the draft National Occupational Research Agenda for Traumatic Injury Prevention. Comments expressing support or with specific recommendations to improve the Agenda are requested. A copy of the draft Agenda is available at https:// www.regulations.gov (search Docket Number CDC–2017–0104). Frank Hearl, Chief of Staff, National Institute for Occupational Safety and Health, Centers for Disease Control and Prevention. [FR Doc. 2017–26359 Filed 12–6–17; 8:45 am] BILLING CODE 4163–19–P DEPARTMENT OF HEALTH AND HUMAN SERVICES Administration for Children and Families Submission for OMB Review; Comment Request Title: Annual Statistical Report on Children in Foster Homes and Children in Families Receiving Payment in Excess of the Poverty Income Level from a State Program Funded under Part A of Title IV of the Social Security Act. OMB No.: 0970–0004. Description: The Department of Health and Human Services is required to collect these data under section 1124 of Title I of the Elementary and Secondary Education Act of 1965, as amended by Public Law 114–95. The data are used by the U.S. Department of Education for allocation of funds for programs to aid disadvantaged E:\FR\FM\07DEN1.SGM 07DEN1

Agencies

[Federal Register Volume 82, Number 234 (Thursday, December 7, 2017)]
[Notices]
[Pages 57757-57758]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2017-26399]



[[Page 57757]]

=======================================================================
-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Centers for Disease Control and Prevention

[30Day-17-17ACE]


Agency Forms Undergoing Paperwork Reduction Act Review

    In accordance with the Paperwork Reduction Act of 1995, the Centers 
for Disease Control and Prevention (CDC) has submitted the information 
collection request titled Medication-Assisted Treatment (MAT) for 
Opioid Use Disorders Study to the Office of Management and Budget (OMB) 
for review and approval. CDC previously published a ``Proposed Data 
Collection Submitted for Public Comment and Recommendations'' notice on 
June, 19, 2017 to obtain comments from the public and affected 
agencies. CDC received three comments related to the previous notice. 
This notice serves to allow an additional 30 days for public and 
affected agency comments.
    CDC will accept all comments for this proposed information 
collection project. The Office of Management and Budget is particularly 
interested in comments that:
    (a) Evaluate whether the proposed collection of information is 
necessary for the proper performance of the functions of the agency, 
including whether the information will have practical utility;
    (b) Evaluate the accuracy of the agencies estimate of the burden of 
the proposed collection of information, including the validity of the 
methodology and assumptions used;
    (c) Enhance the quality, utility, and clarity of the information to 
be collected;
    (d) Minimize the burden of the collection of information on those 
who are to respond, including, through the use of appropriate 
automated, electronic, mechanical, or other technological collection 
techniques or other forms of information technology, e.g., permitting 
electronic submission of responses; and
    (e) Assess information collection costs.
    To request additional information on the proposed project or to 
obtain a copy of the information collection plan and instruments, call 
(404) 639-7570 or send an email to omb@cdc.gov. Direct written comments 
and/or suggestions regarding the items contained in this notice to the 
Attention: CDC Desk Officer, Office of Management and Budget, 725 17th 
Street NW., Washington, DC 20503 or by fax to (202) 395-5806. Provide 
written comments within 30 days of notice publication.

Proposed Project

    Evaluation of Medication-Assisted Treatment (MAT) for Opioid Use 
Disorder--New--National Center for Injury Prevention and Control 
(NCIPC), Centers for Disease Control and Prevention (CDC).

Background and Brief Description

    This is a new Information Collection Request. CDC requests a three-
year OMB approval.
    About 2 million people aged 12 or older in the United States have 
Opioid Use Disorders (OUDs) related to prescription opioids and almost 
600,000 have OUDs related to heroin use (SAMHSA, 2015). OUD is a 
problematic pattern of opioid use that cause significant impairment or 
distress characterized by unsuccessful efforts to control use and 
failures to fulfill obligations social, at work, or school, yet many of 
these people do not receive OUD treatment. Given the continued need for 
treatment and the urgency of the opioid epidemic, further understanding 
of the individual and contextual factors that may impact treatment 
outcomes is needed. To help address this need, the CDC is conducting a 
study of 60 Opioid Use Disorder (OUD) treatment facilities and four 
primary care facilities located in 11 metropolitan statistical areas 
across the United States. The respondent universe includes individuals 
in the United States who receive some form of OUD treatment in the 11 
MSAs.
    Prospective participants will be eligible if they are 18 to 64 
years of age and initiating one of four primary treatments for OUD: 
Methadone maintenance treatment (MMT), buprenorphine (BUP), naltrexone 
(NTX), or counseling treatment without medication (COUN). The study 
aims to enroll 3,560 clients across all sites to better understand the 
relationship between type of Medication Assisted Treatment (MAT) and 
individual and treatment facility characteristics, and contextual 
factors.
    The information gained from this data collection will help inform 
policy makers, communities, and providers on how individual 
characteristics and contextual factors may impact client outcomes. The 
MAT study will also provide a unique perspective for three reasons: (1) 
It assesses the treatment, individual, and contextual factors that 
influence implementation and outcomes in real-world settings; (2) its 
large target sample size (n = 3,560); and, (3) the long follow-up 
window (i.e., 24-month follow-up period with clients). CDC has 
collaborated with other relevant federal agencies to avoid duplication 
and maximize efficiencies in data collection. The MAT Study design and 
protocols have been reviewed and shared with colleagues from the 
Substance Abuse and Mental Health Services Administration (SAMHSA) and 
the National Institute on Drug Abuse (NIDA).
    Four overarching evaluation questions guide the MAT Study. These 
questions drive the research design, and CDC developed this data 
collection effort to, specifically, address these evaluation questions. 
This data collection effort captures a series of outcome measures 
including the associated benefits (e.g., reductions in morbidity, 
mortality, and drug overdoses; improvements in socioeconomic outcomes 
and health-related quality of life [HRQOL]) and potential risks (e.g., 
side effects, diversion potential) of each treatment alternative.
    The study will use a mixed-methods approach using quantitative 
methods such as multilevel latent growth models, propensity score 
matching, latent class analysis and advanced mediation analysis and 
qualitative methods such as interactive coding and analysis for common 
themes.
    The total estimated annualized burden for this collection is 3,093 
hours. The only cost to respondents will be time spent responding to 
the surveys.

                                        Estimated Annualized Burden Hours
----------------------------------------------------------------------------------------------------------------
                                                                                     Number of    Average burden
          Type of respondents                   Form name            Number of     responses per   per response
                                                                    respondents     respondent      (in hours)
----------------------------------------------------------------------------------------------------------------
Clients...............................  Client Screener.........           1,583               1            5/60
                                        Client Check-In.........           1,187               2           15/60

[[Page 57758]]

 
                                        Client Questionnaire               1,187               1           52/60
                                         Baseline.
                                        Client Questionnaire 12-             930               1           45/60
                                         Month Follow-up.
                                        Client Questionnaire 24-             744               1           45/60
                                         Month Follow-up.
                                        Client Focus Groups.....              27               1           90/60
Treatment facility staff..............  Staff Focus Groups......              27               1           90/60
----------------------------------------------------------------------------------------------------------------


Leroy A. Richardson,
Chief, Information Collection Review Office, Office of Scientific 
Integrity, Office of the Associate Director for Science, Office of the 
Director, Centers for Disease Control and Prevention.
[FR Doc. 2017-26399 Filed 12-6-17; 8:45 am]
 BILLING CODE 4163-18-P